Evidence map›Paper›PMID 39858045›Full record

ArticleCancers2025

Multiple Myeloma Cells Shift the Fate of Cytolytic ILC2s Towards TIGIT-Mediated Cell Death.

Fabiana Drommi, Alessia Calabrò, Gaetana Pezzino, Grazia Vento, Josè Freni, Gregorio Costa, Riccardo Cavaliere, Irene Bonaccorsi, Alessandro Allegra, Guido Ferlazzo and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fabiana DrommiLaboratory of Immunology and Biotherapy, Department Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
Alessia CalabròLaboratory of Immunology and Biotherapy, Department Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
Gaetana PezzinoLaboratory of Immunology and Biotherapy, Department Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
Grazia VentoDepartment of Experimental Medicine (DIMES), University of Genoa, 16132 Genova, Italy.
Josè FreniLaboratory of Histology, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy.
Gregorio CostaLaboratory of Immunology and Biotherapy, Department Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
Riccardo CavaliereLaboratory of Immunology and Biotherapy, Department Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
Irene BonaccorsiLaboratory of Immunology and Biotherapy, Department Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
Alessandro AllegraDivision of Hematology, Department of Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, 98125 Messina, Italy.ORCID 0000-0001-6156-8239
Guido FerlazzoDepartment of Experimental Medicine (DIMES), University of Genoa, 16132 Genova, Italy.
Claudia De PasqualeLaboratory of Immunology and Biotherapy, Department Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
Stefania CampanaLaboratory of Immunology and Biotherapy, Department Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, 98125 Messina, Italy.

Funding

Finanziamento Annuale Individuale Attività Base di Ricerca FFABR FFABR-2023Italian Ministry of Health PNRR-MAD-2022-12375909Italian Ministry of Health PNRR-MCNT2-2023-12378122Italian Ministry of Health Ricerca Finalizzata 2018Ministry of Education, University and Research (MIUR) "PRIN 2017"Ministry of Education, University and Research (MIUR) "PRIN 2022"Ministry of Education, University and Research (MIUR),ITALY PRIN 2022 PNRR
6 · The paper itself

Abstract

backgroundGrowing evidence attests to the multifaceted roles of group 2 innate lymphoid cells (ILC2s) in cancer immunity. They exhibit either pro- or anticancer activity depending on tumor type but their function in Multiple Myeloma (MM) is still not elucidated.

methodsThe bone marrow (BM) and peripheral blood (PB) of patients (pts) with MM or precancerous conditions were collected, and specific properties of ILC2 subsets were assessed by flow cytometry.

resultsBy dissecting ILC2s according to c-Kit marker, we observed that NKp30 and NKG2D were mainly confined to c-Kit

conclusionsMM-ILC2s can act as cytolytic immune effectors that are fully competent in PB. However, MM cells shift ILC2 fate towards cell death in BM via the upregulation of TIGIT, thereby representing a potential therapeutic target to restore ILC2 antitumor activity.

Indexed as

DNAM-1granzyme B (GZMB)group 2 innate lymphoid cells (ILC2s)humanmultiple myeloma (MM)TIGIT

Identifiers

PMID39858045
PMCPMC11763689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.